Hair loss treatments, specifically Pyrilutamide and Minoxidil/Finasteride/RU58841. Participants discussed their experiences with them and the results they have seen so far.
An 18-year-old is using a high-dose treatment for hair loss, including 2.5 mg dutasteride, topical minoxidil, and injectable GHK-Cu, despite minimal hair loss. Many users suggest reducing the dutasteride dose due to potential side effects and recommend starting with finasteride instead.
Using PRP or Exosome treatments alongside Finasteride/Dutasteride and Minoxidil may not significantly enhance results. Dutasteride and oral Minoxidil are considered more effective options.
The user is experiencing hair thinning and bald spots, using Nizoral, rosemary oil, fluocinolone, and receiving PRP treatments. They are considering oral minoxidil and finasteride but are hesitant due to age and financial constraints.
The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.
The user shared progress on hair loss treatment between September and November using oral finasteride, topical minoxidil, dermarolling, a LaserComb, caffeine shampoo, Nizoral, scalp massages, and both oral and topical biotin. The conversation discusses the effectiveness of these treatments.
Microneedling for hair loss is discussed, with users mentioning using 0.6mm needles twice a week. Treatments like Minoxidil, finasteride, and RU58841 are implied but not directly mentioned.
The user's hair regrowth plan includes topical treatments (RU58841, azelaic acid, ketoconazole), oral supplements (Gia Herbs, castor oil), microneedling, PTD-DBM peptide with valproic acid, red light therapy, inversion table with scalp massage, and platelet-rich fibrin injections. Commenters suggest that finasteride and minoxidil are essential treatments for male pattern hair loss, which are missing from the plan.
The conversation is about using GHK-CU peptide for hair regrowth. Minoxidil, finasteride, and RU58841 are also mentioned as potential treatments for hair loss.
A user's progress after 3 months of using the "big 4" hair loss treatments - liposomal gel minoxidil, finasteride, keto shampoo and microneedling; with people providing advice about their own experiences and asking for more information.
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.
The user is using a topical solution with finasteride, minoxidil, and tretinoin and is considering adding GHK-Cu to enhance hair growth and quality. Another user suggests diluting GHK-Cu and storing it in a smaller, refrigerated bottle.
KY-19382, an indirubin derivative, is discussed for its potential to stimulate hair growth and create new hair follicles. The conversation seeks experiences with synthesizing, topically applying, or orally administering KY-19382.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
The conversation discusses disappointment in Verteporfin for hair loss treatment, with a mention of an upcoming trial by Dr. Bisanga. No specific treatments were confirmed as used by the original poster.
Exosomes were used for hair loss treatment, showing results 33 days after the second session. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.
The user reported noticeable hair improvement over four months using 1 mg of finasteride and weekly microneedling. Progress photos from October 2024 to January 2025 show positive changes.
People discussed their intense hair loss treatments, including the use of dutasteride, RU58841, minoxidil, tretinoin, essential oils, microneedling, and various topical sprays. Some users reported success with these methods in preventing hair loss and stimulating hair growth.
The user has been using Minoxidil and Finasteride for over a year with limited success and is now trying microneedling. They seek advice on using hyaluronic acid to help the microneedling pen glide smoothly on the scalp.
The user reports positive results using a multi-peptide serum for hair density, combined with finasteride and melatonin, after stopping minoxidil. They experienced hair regrowth after previously losing hair despite using finasteride and minoxidil.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
Follica's preferred microneedling protocol for hair growth, which includes needle depth, frequency and movement parameters as well as the use of topical treatments such as minoxidil and finasteride.
Hair mesotherapy with dutasteride is popular in Europe and can be effective, especially when combined with oral dutasteride. Some users suggest using topical dutasteride with microneedling as an alternative, though it may be painful.
The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.
The conversation discusses the availability of Breezula, a drug for hair loss, now being sold as an acne treatment, and whether it can be applied to the scalp. Users express skepticism about new hair loss treatments and suggest waiting for FDA approval.
A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.